Author Archives: admin


Global Allogeneic Stem Cells Market 2020-2024 | Evolving Opportunities with Biosolution Co. Ltd. and Cynata Therapeutics Ltd. | Technavio – Business…

LONDON--(BUSINESS WIRE)--Technavio has been monitoring the global allogeneic stem cells market and the market is poised to grow by USD 1.24 billion during 2020-2024 at a CAGR of over 12% during the forecast period. Request Free Sample Pages

Read the 131-page research report with TOC on "Allogeneic Stem Cells Market Analysis Report by geography (Asia, Europe, North America, and ROW), by application (regenerative therapy and drug discovery and development), and segment forecasts, 2020-2024".

https://www.technavio.com/report/allogeneic-stem-cells-market-industry-analysis

The new product approvals and special drug designations are anticipated to boost the growth of the market. Based on the application, the allogeneic stem cells market has been segmented into regenerative therapy and drug discovery and development. Manufacturers are increasingly emphasizing innovations and improvisation in the development of regenerative therapies. Many of the regenerative therapeutic candidates have obtained approval for clinical trials in the US, Europe, and APAC due to the efficacy of allogeneic stem cell therapeutics. This is encouraging market players to launch new product lines to stimulate the overall product demand for stem or regenerative therapy using allogeneic stem cell therapeutics and provide better options for their customers. Thus, new product approvals are expected to drive market growth during the forecast period.

Buy 1 Technavio report and get the second for 50% off. Buy 2 Technavio reports and get the third for free.

View market snapshot before purchasing

Major Five Allogeneic Stem Cells Market Companies:

Biosolution Co. Ltd.

Biosolution Co. Ltd. is headquartered in South Korea (Republic of Korea) and operates the business under its Unified business segment. The company offers an allogeneic keratinocyte spread medication, Keraheal-Allo, that promotes skin regeneration.

Cynata Therapeutics Ltd.

Cynata Therapeutics Ltd. is engaged in the discovery, development, licensing, manufacturing, marketing, distribution, and sales of innovative therapeutics for the treatment of various diseases. The company provides a mesenchymal stem cell product, Cymerus, which is used to treat graft-versus-host disease.

JCR Pharmaceuticals Co. Ltd.

JCR Pharmaceuticals Co. Ltd. is headquartered in Japan and operates under two business segments, namely Pharmaceuticals, and Medical Devices and Laboratory Equipment. The company offers a regenerative medical product, TEMCELL HS Injection, which uses human mesenchymal stem cells for the treatment of acute graft-versus-host disease.

Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc. is headquartered in the US and offers products through its Unified business segment. The company provides OpRegen, which is currently being tested in a Phase I/IIa clinical trial. This product is intended for the treatment of dry AMD.

MEDIPOST Co. Ltd.

MEDIPOST Co. Ltd. is headquartered in South Korea (Republic of Korea) and offers products through its Unified business segment. The company provides an allogeneic umbilical cord blood-derived mesenchymal stem cell drug, CARTISTEM, which is used for the treatment of knee cartilage defects.

Register for a free trial today and gain instant access to 17,000+ market research reports. Technavio's SUBSCRIPTION platform

Allogeneic Stem Cells Application Outlook (Revenue, USD Million, 2020-2024)

Allogeneic Stem Cells Regional Outlook (Revenue, USD Million, 2020-2024)

Technavios sample reports are free of charge and contain multiple sections of the report, such as the market size and forecast, drivers, challenges, trends, and more. Request a free sample report

Related Reports on Health Care include:

Cancer Stem Cell Therapeutics Market Global Cancer Stem Cell Therapeutics Market by type (allogeneic stem cell transplant and autologous stem cell transplant) and geography (Asia, Europe, North America, and ROW).

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focus on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavios report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavios comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Read the original:
Global Allogeneic Stem Cells Market 2020-2024 | Evolving Opportunities with Biosolution Co. Ltd. and Cynata Therapeutics Ltd. | Technavio - Business...

3D Cell Culture Market: Hydrogel, Hanging Drop, Bioreactor, Microfluidics, Magnetic Levitation – Global Forecast to 2024 – ResearchAndMarkets.com -…

DUBLIN--(BUSINESS WIRE)--The "3D Cell Culture Market by Product (Hydrogel, Hanging Drop, Bioreactor, Microfluidics, Magnetic Levitation), Application (Cancer, Stem Cell, Toxicology, Tissue Engineering), End User (Pharmaceutical, Biotech, Cosmetics), Region - Global Forecast to 2024" report has been added to ResearchAndMarkets.com's offering.

The 3D cell culture market is projected to reach USD 1,846 million by 2024 from USD 892 million in 2019, at a CAGR of 15.7%

The growth in this market is primarily driven by the increasing focus on developing alternatives to animal testing, growing focus on personalized medicine, increasing incidence of chronic diseases, and the availability of funding for research. On the other hand, the lack of infrastructure for 3D cell-based research and the high cost of cell biology research are expected to limit market growth during the forecast period.

The microfluidics-based 3D cell cultures segment is projected to grow at the highest CAGR during the forecast period.

Based on product, the 3D cell culture market is segmented into scaffold-based, scaffold-free, microfluidics-based, and magnetic & bioprinted 3D cell cultures. The microfluidics-based segment is expected to register the highest CAGR during the forecast period. Funding initiatives from various government and private investors are among the key factors driving the growth of this market.

Cancer and stem cell research segment accounted for the largest share of the 3D cell culture market in 2018.

On the basis of application, the 3D cell culture market is segmented into cancer & stem cell research, drug discovery & toxicology testing, and tissue engineering & regenerative medicine. Cancer & stem cell research segment accounted for the largest share of the market in 2018. The increasing prevalence of cancer and significant funding initiatives for cancer research from the government as well as the private sector are some of the major factors driving the growth of this application segment.

Europe to witness high growth during the forecast period.

Based on the region, the 3D cell culture market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). The European market is expected to grow at the highest CAGR owing to the growth of the pharmaceutical and biotechnology industry, increasing incidence of cancer, growing number of venture capital investments, strategic expansion of market players in the region, recent commercialization of microfluidic-based products, increasing presence of major market players, and the large number of research activities in the region.

Market Dynamics

Market Drivers

Restraints

Opportunities

Challenges

Company Profiles

Other Key Players

For more information about this report visit https://www.researchandmarkets.com/r/aj5kod

See more here:
3D Cell Culture Market: Hydrogel, Hanging Drop, Bioreactor, Microfluidics, Magnetic Levitation - Global Forecast to 2024 - ResearchAndMarkets.com -...

Functional "Mini-liver" Created By 3D Bioprinting – Technology Networks

Using human blood cells, Brazilian researchers have succeeded in obtaining hepatic organoids (mini-livers) that perform all of the livers typical functions, such as producing vital proteins, storing vitamins, and secreting bile, among many others. The innovation permits the production of hepatic tissue in the laboratory in only 90 days and may in the future become an alternative to organ transplantation.

The study was conducted at the Human Genome and Stem Cell Research Center (HUG-CELL). Hosted by the University of So Paulo (USP), HUG-CELL is one of the Research, Innovation and Dissemination Centers (RIDCs) funded by FAPESP.

This study combined bioengineering techniques, such as cell reprogramming and the cultivation of pluripotent stem cells, with 3D bioprinting. Thanks to this strategy, the tissue produced by the bioprinter maintained hepatic functions for longer than reported by other groups in previous studies.

More stages have yet to be achieved until we obtain a complete organ, but were on the right track to highly promising results. In the very near future, instead of waiting for an organ transplant, it may be possible to take cells from the patient and reprogram them to make a new liver in the laboratory. Another important advantage is zero probability of rejection, given that the cells come from the patient, said Mayana Zatz,director of HUG-CELL and last author of the article published in Biofabrication.

The innovative part of the study resided in how the cells were included in the bioink used to produce tissue in the 3D printer. Instead of printing individualized cells, we developed a method of grouping them before printing. These clumps of cells, or spheroids, are what constitute the tissue and maintain its functionality much longer, said Ernesto Goulart, a postdoctoral fellow in USPs Institute of Biosciences and first author of the article.

The researchers thereby avoided a problem faced by most human tissue bioprinting techniques, namely, the gradual loss of contact among cells and hence loss of tissue functionality.

Spheroid formation in this study already occurred in the differentiation process, when pluripotent cells were transformed into hepatic tissue cells (hepatocytes, vascular cells, and mesenchymal cells). We started the differentiation process with the cells already grouped together. They were cultured in agitation, and groups formed spontaneously, Goulart told Agncia FAPESP.

A liver in 90 days

According to the researchers, the complete process from collection of the patients blood to functional tissue production takes approximately 90 days and can be divided into three stages: differentiation, printing, and maturation.

Initially, the blood cells are reprogrammed to regress to a stage of pluripotency characteristic of stem cells, becoming induced pluripotent stem cells (iPSCs). Japanese scientist Shinya Yamanaka was awarded the 2012 Nobel Prize for Medicine for developing this technique.

The next stage consists of inducing differentiation into liver cells. The spheroids are then mixed with bioink, a hydrogel-like fluid, and printed out. The resulting structures mature in culture for 18 days.

The printing process entails the deposition of spheroids along three axes, which is necessary for the material to gain volume and give the tissue proper support, Goulart said. The gel-like bioink is crosslinked to make the structures more rigid so that they can be manipulated and even sutured.

Most of the available methods for printing live tissue use immersion and cell dispersion in a hydrogel to recapitulate the microenvironment and ensure tissue functionality. However, experiments have shown that loss of cell contact and functionality tends to occur when dispersion is performed cell by cell.

Its a somewhat traumatic process for the cells, which need time to get used to the environment and acquire functionality, Goulart said. At this stage, they arent tissue yet because theyre dispersed, but as shown by our study, they already have the capacity to clear the blood of toxins and to produce and secrete albumin [a protein produced only by the liver], for example.

In this study, researchers developed mini-livers using blood cells from three volunteers as raw material and compared markers relating to functionality, such as the maintenance of cell contact and protein production and release. Our spheroids worked much better than those obtained from single-cell dispersion. As expected, during maturation, the markers of hepatic function were not reduced, Goulart said.

Although the study was limited to producing miniature livers, the technique can be used in the future to produce complete organs suitable for transplantation, according to Goulart. We did it on a small scale, but with investment and interest, it can easily be scaled up, he said.Reference:Goulart, E., de Caires-Junior, L. C., Telles-Silva, K. A., Araujo, B. H. S., Rocco, S. A., Sforca, M., Zatz, M. (2019). 3D bioprinting of liver spheroids derived from human induced pluripotent stem cells sustain liver function and viability in vitro. Biofabrication, 12(1), 015010. https://doi.org/10.1088/1758-5090/ab4a30

This article has been republished from the following materialsoriginally published byFAPESP Agencyaccording toCreative Commons license CC-BY-NC-ND. Note: material may have been edited for length and content. For further information, please contact the cited source.

See the original post here:
Functional "Mini-liver" Created By 3D Bioprinting - Technology Networks

Scientists hope MND cure is a step closer after stem cell breakthrough discovery – The National

SCIENTISTS hope a cure for motor neurone disease (MND) is a step closer after a research breakthrough identified cells key to the degenerative condition.

There is currently no known cure for MND, which causes signals from motor neurone nerve cells in the brain and spinal cord needed to control movement to gradually stop reaching the muscles.

Notable people who have lived with MND include Scottish rugby star Doddie Weir and Stephen Hawking.

Researchers used stem cell technology to identify a type of cell that can cause motor neurones to fail.

Using stem cells from patient skin samples, they found glial cells, which normally support neurones in the brain and spinal cord, become damaging to motor neurones in the patients with the condition.

By testing different combinations of glial cells and motor neurones grown together in the lab, researchers found glial cells from MND patients can cause motor neurones in healthy people to stop producing the electrical signals needed to control muscles.

READ MORE:BBCSports Personality of the Year award to honour Doddie Weir

Gareth Miles, a professor of neuroscience at the University of St Andrews, helped lead the joint project with the University of Edinburgh.

Miles said: We are very excited by these new findings, which clearly point the finger at glial cells as key players in this devastating disease.

Interestingly, the negative influence of glial cells seems to prevent motor neurones from fulfilling their normal roles, even before the motor neurones show signs of dying.

We hope that this new information highlights targets for the development of much-needed treatments and ultimately a cure for MND.

The joint research was published in the scientific journal Glia.

View original post here:
Scientists hope MND cure is a step closer after stem cell breakthrough discovery - The National

Stem Cell Banking Market: Adopts Innovation to Stay Competitive Forecast – Market Research Sheets

Global Stem Cell Banking, Market Size, Status and Forecast 2018-2026 offers a primary overview of the Stem Cell Banking, industry covering Definition, Classification, Industry Value, Price, Cost and Gross Profit, Share via Region, New Challenge Feasibility Evaluation, Analysis and Guidelines on New mission Investment. Stem Cell Banking, Market report presents in-intensity insight of Company Profile, Capacity, Product Specifications, Production Value, Sales, Revenue, Price, Gross Margin, Market Size and Market Shares for topmost prime key vendors (Allergan, Plc., Galderma S.A., Integra LifeSciences Corporation, Merz Pharma GmbH & Co. KGaA., Sanofi S.A., SciVision Biotech Inc., Sinclair Pharma Plc., Suneva Medical, Valeant Pharmaceuticals International, Inc., and Anika Therapeutics, Inc.). In the end, there are 4 key segments covered in this Stem Cell Banking, market report: competitor segment, product type segment, end use/application segment and geography segment.

Target Audience of Stem Cell Banking, Market: Suppliers, Channel Partners, Production Companies, Market Consultants, Marketing Authorities, Research Institutions, Subject Matter Experts, Financial Institutions, Government Authorities.

To Get the Concise Free Sample PDF of the Stem Cell Banking, Market Report, Along With the TOC, Statistics, and Tables Please Visit

Stem Cell Banking, Market Summary: This report includes the estimation of market size for value (million US$) and volume (K sqm). Both top-down and bottom-up approaches have been used to estimate and validate the market size of Stem Cell Banking, market, to estimate the size of various other dependent submarkets in the overall market. Key players in the market have been identified through secondary research, and their market shares have been determined through primary and secondary research. All percentage shares, splits, and breakdowns have been determined using secondary sources and verified primary sources.

Based on Classifications, each type is studied as Sales, Stem Cell Banking, Market Share (%), Revenue (Million USD), Price, Gross Margin and more similar information. each type, including:

Stem Cell Banking, Market: Regional Analysis Includes:

Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

Europe (Turkey, Germany, Russia UK, Italy, France, etc.)

North America (the United States, Mexico, and Canada.)

South America (Brazil etc.)

The Middle East and Africa (GCC Countries and Egypt.)

Stem Cell Banking, Market Capacity, Production, Revenue, Consumption, Export and Import (2018-2026)

Stem Cell Banking, Market Capacity, Production and Growth

Production, Consumption, Export and Import

Revenue and Growth of Market

Stem Cell Banking, Market Forecast (2018-2026)

Stem Cell Banking, Market by Capacity, Production, Revenue Forecast

Production Forecast by Type and Price Forecast

Consumption Forecast by Application

Production, Import, Export and Consumption Forecast

Stem Cell Banking, Market Production, Consumption, Import and Export Forecast by Regions (Provinces)

For Better Understanding Go With This Free Sample Report

ABOUT USCOMPANY OVERVIEW

Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. Our client base includes players from across all business verticals in over 150 countries worldwide. We are uniquely positioned to help businesses around the globe deliver practical and lasting results through various recommendations about operational improvements, technologies, emerging market trends and new working methods.

We offer both customized and syndicated market research reports that help our clients create visionary growth plans to provide traction to their business. We meticulously study emerging trends across various industries at both the global and regional levels to identify new opportunities for our clientele. Our global team of over 100 research analysts and freelance consultants provide market intelligence from the very molecular country level and also provide a global perspective of the market.

Our team is of the most vital cog in our robust machinery that gives us the ability to deliver independent insight relying on our cognitive defusion training module. This allows for an objective and unbiased assessment of the market. We pride ourselves in my constantly striving to update our extremely in-depth understanding of the market by closely monitoring and analyzing markets, trends, and emerging best practices, across allfathomable industries under the sun. This enables us to equip our valued clientele with key decisive inputs to capitalize on lucrative growth opportunities in the market and to follow firmly position themselves on a high growth path in the future.

Contact Us:

Name: Mr. Raj Shah

Phone: US +12067016702 / UK +4402081334027

Email: [emailprotected]

Visit our Blog: https://hospitalhealthcareblog.wordpress.com/

This post was originally published on Market Research Sheets

More:
Stem Cell Banking Market: Adopts Innovation to Stay Competitive Forecast - Market Research Sheets

Stem Cell Discovery Could Transform Treatment of Tendon Injuries – Gilmore Health News

In recent research published in the Journal Nature Cell Biology, scientists discovered stem cells that could help regenerate tendon cells following an injury.

Tendons are connective tissue in the body that joins muscles to the bones. They facilitate movement and help to promote stability. However, tendons are prone to injuries.

Read Also: The Exciting Future of Joint and Cartilage Repair

Knee Injury

Tendon injuries, including rotator cuff tear and jumpers knee, are usually painful. They take time to heal and could even lead to secondary ruptures.

In fact, people rarely fully recover from these injuries. This means that patients may have to endure long-term pain and reduced mobility.

Scientists have battled to understand why tendon injuries are difficult to recover compared to other types of injury. They found out that the buildup of fibrous scar tissue is what stands in the way. Some also thought that the connective tissue probably lack stem cells, making it hard for injury to fully heal.

Now, researchers at the Carnegie Institution for Science have discovered that tendon stem cells do exist. This finding could help boost healing and possibly remove the need for surgery in case of these injuries.

Read Also: HGH Found to Promote Recovery from Spinal Damage

Because tendon injuries rarely heal completely, it was thought that tendon stem cells might not exist, said lead author Tyler Harvey, a developmental cell biologist. Many searched for them to no avail, but our work defined them for the first time.

The research team was able to identify all cell types in the Patellar tendon, located below the kneecap. It identified tendon stem cells that were not known to exist previously among these cell types.

Stem cells are cells that have yet to differentiate fully to serve a specific purpose or function. They are capable of regenerating to form new cells that support the function of the tissue they are associated with.

Almost all tissue types were known to have these cells, but none was linked to the tendon.

The Carnegie team found that the Patellar tendon harbors a group of cells called Tppp3+. That name is the short form for tubulin polymerization-promoting protein family member 3-expressing cells.

These cells help to generate new tendon cells known as tenocytes, the researchers said. Also, they are capable of self-renewing when there is an injury.

This discovery is an interesting one. It means tendon stem cells could potentially find use in promoting natural regeneration.

However, the scientists found that a receptor may stand in the way of tendon healing, though. Recovery may slow to a halt when platelet-derived growth factor receptor alpha becomes inactive.

Certain Tppp3+ cells express the Pdfgra receptor.

A protein known as platelet-derived growth factor-A activates the receptor. When this happens, it stimulates both tendon stem cells and fibrous scar tissue cells. These effects make it somewhat clearer to see why tendon injury does not heal easily.

Read Also: Weekly Steroid Doses Can Repair and Strengthen Injured Muscles

When the receptor on tendon stem cells gets turned off, the formation of new tendon cells following an injury stops. This gives room for only scar tissue to form.

Tendon stem cells exist, but they must outcompete the scar tissue precursors in order to prevent the formation of difficult, fibrous scars, lead researcher Chen-Ming Fan said.

The team leader said that being able to find a way of blocking scar-forming cells while boosting Tppp3+ cells may help immensely. He said such a therapy could turn out a game-changer in the treatment of tendon injuries.

Before such therapy could emerge, it is needed to replicate these results in humans.

https://www.nature.com/articles/s41556-019-0417-z

PRP and HGH Are Now Used by Athletes to Speed up Healing After Major Injuries

HGH Supplements Like Genf20 Plus, Somatropinne and Hypergh 14x May Get Athletes Banned

HGH Deficiency Symptoms And Latest Testing Options

Understanding The Role Of HGH In Treating Burns

HGH May Help Heal Age-Induced Tissue Damage By Activating Vital Gene

Here is the original post:
Stem Cell Discovery Could Transform Treatment of Tendon Injuries - Gilmore Health News

Global Stem Cell Therapy Market to Surpass US$ 40.3 Billion by 2027 Coherent Market Insights – Business Wire

SEATTLE--(BUSINESS WIRE)--According to Coherent Market Insights, the global stem cell therapy market was valued at US$ 7,313.6 million in 2018, and is expected to exhibit a CAGR of 21.1% over the forecast period (2019-2027).

Key Trends and Analysis of the Stem cell therapy Market:

Key trends in market are increasing incidence of cancer and osteoporosis, rising number of research and development activities for product development, and adoption of growth strategies such as acquisitions, collaborations, product launches by the market players.

Key players are focused on launches of production facility for offering better stem cell therapy in the potential market. For instance, in January 2019, FUJIFILM Cellular Dynamics, Inc., a subsidiary of FUJIFILM Corporation, announced to invest around US$ 21 Mn for building new cGMP-compliant production facility, in order to enhance production capacity of induced pluripotent stem (iPS) cell for the development of cell therapy and regenerative medicine products. The new facility is expected to begin its operations by March 2020.

Request your Sample copy @ https://www.coherentmarketinsights.com/insight/request-sample/2848

Market players are adopting inorganic growth strategies such as acquisitions and collaborations, in order to enhance their offerings in the potential market. For instance, in August 2019, Bayer AG acquired BlueRock Therapeutics, a company developing cell therapies based on induced pluripotent stem cell (iPSC) platform. This acquisition is expected to strengthen Bayers market position in the stem cell therapy market.

Furthermore, increasing research and development activities of stem cells by research organizations to provide efficient treatment options to patients suffering from various chronic diseases is expected to drive growth of the stem cell therapy market over the forecast period. For instance, in January, 2019, the Center for Beta Cell Therapy in Diabetes and ViaCyte, Inc. initiated a trial of human stem cell-derived product candidates in type 1 diabetes patients in Europe.

However, high cost of preservation of stem cells and other factors is expected to hamper growth of stem cell therapy market over the forecast period. High cost of stem cell storage is a factor that is expected to hinder growth of the market. For instance, according to the Meredith Corporation, a private bank generally charges US$ 1,200 to US$ 2,300 to collect cord blood at the time of delivery, with annual storage fees of US$ 100 to US$ 300 each year. Thus, high cost associated with stem cell storage combined with high production cost are expected to hinder growth of the market, especially in emerging economies.

Key Market Takeaways:

Buy this Report (Single User License) @ https://www.coherentmarketinsights.com/insight/buy-now/2848

Market Segmentations:

The rest is here:
Global Stem Cell Therapy Market to Surpass US$ 40.3 Billion by 2027 Coherent Market Insights - Business Wire

The 3D cell culture market is projected to reach USD 1,846 million by 2024 from USD 892 million in 2019, at a CAGR of 15.7% – PRNewswire

NEW YORK, Dec. 17, 2019 /PRNewswire/ -- The global 3D cell culture market is projected to grow at a CAGR of 15.7% during the forecast period.

Read the full report: https://www.reportlinker.com/p05206182/?utm_source=PRN

The 3D cell culture market is projected to reach USD 1,846 million by 2024 from USD 892 million in 2019, at a CAGR of 15.7%. The growth in this market is primarily driven by the increasing focus on developing alternatives to animal testing, growing focus on personalized medicine, increasing incidence of chronic diseases, and the availability of funding for research. On the other hand, the lack of infrastructure for 3D cell-based research and the high cost of cell biology research are expected to limit market growth during the forecast period.

The microfluidics-based 3D cell cultures segment is projected to grow at the highest CAGR during the forecast period.Based on product, the 3D cell culture market is segmented into scaffold-based, scaffold-free, microfluidics-based, and magnetic & bioprinted 3D cell cultures.The microfluidics-based segment is expected to register the highest CAGR during the forecast period.

Funding initiatives from various government and private investors are among the key factors driving the growth of this market.

The cancer and stem cell research segment accounted for the largest share of the 3D cell culture market in 2018.On the basis of application, the 3D cell culture market is segmented into cancer & stem cell research, drug discovery & toxicology testing, and tissue engineering & regenerative medicine.The cancer & stem cell research segment accounted for the largest share of the market in 2018.

The increasing prevalence of cancer and significant funding initiatives for cancer research from the government as well as the private sector are some of the major factors driving the growth of this application segment.

Europe to witness high growth during the forecast period.Based on region, the 3D cell culture market is segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW). The European market is expected to grow at the highest CAGR owing to the growth of the pharmaceutical and biotechnology industry, increasing incidence of cancer, growing number of venture capital investments, strategic expansion of market players in the region, recent commercialization of microfluidic-based products, increasing presence of major market players, and the large number of research activities in the region.

The primary interviews conducted for this report can be categorized as follows: By Company Type: Tier 1: 50%, Tier 2: 30%, and Tier 3: 20% By Designation: C-level: 37%, D-level: 29%, and Others: 34% By Region: North America: 38%, Europe: 23%, Asia: 30%, and the RoW: 9%

List of companies profiled in this report Thermo Fisher Scientific (US) Corning Incorporated (US) Merck (Germany) Lonza AG (Switzerland) REPROCELL Incorporated (Japan) TissUse (Germany) InSphero (Switzerland) Synthecon (US) 3D Biotek (US) CN Bio (UK) Hamilton Company (US) MIMETAS (Netherlands) Emulate (US) Hrel Corporation (US) QGel SA (Switzerland) SynVivo (US) Advanced BioMatrix (US) Greiner Bio-One International (Austria) PromoCell (Germany)

Research Coverage:The report provides an overview of the 3D cell culture market.It aims at estimating the market size and growth potential of this market across different segments such as product, application, end user, and region.

The report also includes an in-depth competitive analysis of the key players in the market, along with their company profiles, recent developments, and key market strategies.

Key Benefits of Buying the Report:The report will help the market leaders/new entrants in the 3D cell culture market by providing them with the closest approximations of revenues for the overall market and its subsegments.This report will help stakeholders to understand the competitive landscape better and gain insights to position their businesses and help companies adopt suitable go-to-market strategies.

The report also helps stakeholders understand the pulse of the market and provide them with information regarding key market drivers and opportunities.

Read the full report: https://www.reportlinker.com/p05206182/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker

http://www.reportlinker.com

Follow this link:
The 3D cell culture market is projected to reach USD 1,846 million by 2024 from USD 892 million in 2019, at a CAGR of 15.7% - PRNewswire

Gene Therapy for Sickle-Cell Anemia Looks Promisingbut It’s Riddled With Controversy – Singularity Hub

Gene therapy is fighting to enter mainstream medicine. With sickle cell disease, the fight is heating up.

Roughly two years ago, the FDA made the historic decision to approve the first gene therapy in the US, finally realizing the therapeutic potential of hacking our biological base code after decades of cycles of hope and despair. Other approvals soon followed, including Luxturna to target inherited blindness and Zolgensma, a single injection that could save children with a degenerative disease from their muscles wasting away and dying before the age of two.

Yet despite their transformative potential, gene therapy has only targeted relatively rareand often fataldisorders. Thats about to change.

This year, a handful of companies deployed gene therapy against sickle-cell anemia, a condition that affects over 20 million people worldwide and 100,000 Americans. With over a dozen therapies in the run, sickle-cell disease could be the indication that allows gene therapy to enter the mainstream. Yet because of its unique nature, sickle-cell could also be the indication that shines an unflinching spotlight on challenges to the nascent breakthrough, both ethically and technologically.

You see, sickle-cell anemia, while being one of the worlds best-known genetic diseases, and one of the best understood, also predominantly affects third-world countries and marginalized people of color in the US. So far, gene therapy has come with a hefty bill exceeding millions; few people afflicted by the condition can carry that amount. The potential treatments are enormously complex, further upping costs to include lengthy hospital stays, and increasing potential side effects. To muddy the waters even more, the disorder, though causing tremendous pain and risk of stroke, already has approved pharmaceutical treatments and isnt necessarily considered life-threatening.

How we handle gene therapies for sickle-cell could inform many other similar therapies to come. With nearly 400 clinical trials in the making and two dozen nearing approval, theres no doubt that hacking our genes will become one of the most transformative medical wonders of the new decade. The question is: will it ever be available for everyone in need?

Even those uninterested in biology have likely heard of the disorder. Sickle-cell anemia holds the crown as the first genetic disorder to be traced to its molecular roots nearly a hundred years ago.

The root of the disorder is a single genetic mutation that drastically changes the structure of the oxygen-carrying protein, beta-globin, in red blood cells. The result is that the cells, rather than forming their usual slick disc-shape, turn into jagged, sickle-shaped daggers that damage blood vessels or block them altogether. The symptoms arent always uniform; rather, they come in crisis episodes during which the pain becomes nearly intolerable.

Kids with sickle-cell disorder usually die before the age of five; those who survive suffer a lifetime of debilitating pain and increased risk of stroke and infection. The symptoms can be managed to a degree with a cocktail of drugsantibiotics, painkillers, and a drug that reduces crisis episodes but ups infection risksand frequent blood transfusions or bone marrow transplants. More recently, the FDA approved a drug that helps prevent sickled-shaped cells from forming clumps in the vessels to further combat the disorder.

To Dr. David Williams at Boston Childrens Hospital in Massachusetts, the availability of these treatmentshowever inadequatesuggests that gene therapy remains too risky for sickle-cell disease. Its not an immediately lethal diseaseit wouldnt be ethical to treat those patients with a highly risky experimental approach, he said to Nature.

Others disagree. Freeing patients from a lifetime of risks and pain seems worthy, regardless of the price tag. Inspired by recent FDA approvals, companies have jumped onto three different treatments in a bitter fight to be the first to win approval.

The complexity of sickle-cell disease also opens the door to competing ideas about how to best treat it.

The most direct approach, backed by Bluebird Bio in Cambridge, Massachusetts, uses a virus to insert a functional copy of the broken beta-globin gene into blood cells. This approach seems to be on track for winning the first FDA approval for the disorder.

The second idea is to add a beneficial oxygen-carrying protein, rather than fixing the broken one. Here, viruses carry gamma-globin, which is a variant mostly present in fetal blood cells, but shuts off production soon after birth. Gamma-globin acts as a repellent that prevents clotting, a main trigger for strokes and other dangerous vascular diseases.

Yet another idea also focuses on gamma-globin, the good guy oxygen-carrier. Here, rather than inserting genes to produce the protein, the key is to remove the breaks that halt its production after birth. Both Bluebird Bio and Sangamo Therapeutics, based in Richmond, California, are pursing this approach. The rise of CRISPR-oriented companies is especially giving the idea new promise, in which CRISPR can theoretically shut off the break without too many side effects.

But there are complications. All three approaches also tap into cell therapy: blood-producing cells are removed from the body through chemotherapy, genetically edited, and re-infused into the bone marrow to reconstruct the entire blood system.

Its a risky, costly, and lengthy solution. Nevertheless, there have already been signs of success in the US. One person in a Bluebird Bio trial remained symptom-free for a year; another, using a CRISPR-based approach, hasnt experienced a crisis in four months since leaving the hospital. For about a year, Bluebird Bio has monitored a dozen treated patients. So far, according to the company, none has reported episodes of severe pain.

Despite these early successes, advocates worry about the actual impact of a genetic approach to sickle-cell disease.

Similar to other gene therapies, the treatment is considered a last-line, hail Mary solution for the most difficult cases of sickle cell disease because of its inherent risks and costly nature. Yet end-of-the-line patients often suffer from kidney, liver, and heart damages that make chemotherapy far too dangerous.

Then theres the problem of global access. Some developing countries, where sickle-cell disease is more prevalent, dont even have consistent access to safe blood transfusions, not to mention the laboratory equipment needed for altering blood-producing stem cells. Recent efforts in education, early screening, and prevention have also allowed people to live longer and reduce the stigma of the disorder.

Is a $1 million price tag ever attainable? To combat exhorbitant costs, Bluebird Bio is offering an installment payment plan for five years, which can be terminated anytime the treatment stops working. Yet for patients in South Africa, India, or Cambodia, the costs far exceed the $3 per month price tag for standard treatment. Even hydroxyurea, the newly-approved FDA drug to reduce crisis pain episodes, is just a fraction of the price tag that comes with gene therapy.

As gene therapy technologies are further refined and their base cost reduced, its possible that overall costs will drop. Yet whether these treatments will be affordable in the long run remains questionable. Even as scientists focus on efficacy rather than price tag, NIH director Dr. Francis Collins believes not thinking about global access is almost unethical. There are historical examples for optimism: vaccines, once rather fringe, now touch almost every corner of our world with the help of scientific knowledge, advocacy groups, andfundamentallyproven efficacy.

With the rise of gene therapy, were now in an age of personalized medicine beyond imagination. Its true that perhaps sickle-cell disease genetic therapies arent quite there yet in terms of safety and efficacy; but without tackling access issues, the therapy will be stymied in its impact for global good. As genetic editing tools become more powerful, gene therapy has the potential to save even more livesif its made accessible to those who need it most.

Image Credit: Image by Narupon Promvichai from Pixabay

Link:
Gene Therapy for Sickle-Cell Anemia Looks Promisingbut It's Riddled With Controversy - Singularity Hub

Orthopaedic Surgeon, Dr. Jeffrey Carlson, first in Central and Eastern Virginia to implant the M6-C Artificial Cervical Disc – BioSpace

NEWPORT NEWS, Va., Dec. 18, 2019 /PRNewswire/ -- Orthopaedic and Spine Center announced Dr. Jeffrey Carlson, Orthopaedic Spine Surgeon, became the first surgeon in Central and Eastern Virginia area to implant the M6-Cartificial cervical disc. The outpatient surgery was performed on a 53 year old female at Bon Secours/Mercy Health Mary Immaculate Hospital in Newport News, Virginia on November 20, 2019.

The patient reported symptoms of severe neck pain which radiated to both shoulders after a motor vehicle accident. After she failed to respond to conservative treatment, an MRI was ordered revealing severe spinal stenosis and spinal cord abutment at level C3-4 caused by a herniated disc. In consultation with Dr. Carlson, the patient made the decision to have cervical disc arthroplasty, using the Orthofix M6-C artificial cervical disc.

"I've been waiting for the right patient with the appropriate diagnosis to employ the M6-C disc," said Carlson. "The technology used in this procedure facilitates a speedy recovery with minimal limitations and a great outcome, so that my patient can get back to her active life. She just had her two week post-surgical follow-up appointment - her recovery is going very well and she feels much relief from the severe pain she once experienced."

The M6-C disc received U.S. Food and Drug Approval in February 2019.It was designed to closely mimic the anatomic structure of a natural disc as well as provide an effective alternative to a spinal fusion. By allowing the spine to move naturally, the M6-C artificial disc potentially minimizes stress to adjacent discs and other vertebral structures.

About Jeffrey R. Carlson, M.D.Dr. Jeffrey Carlson has been a part of Orthopaedic & Spine Center since 1999 and serves as the President and Managing Partner. He is a board-certified, fellowship-trained orthopaedic surgeon who focuses on the treatment of injuries and disorders of the spine.

About Orthopaedic & Spine CenterOrthopaedic & Spine Center (OSC) is staffed by outstanding medical professionals who strive to provide the very best orthopaedic and interventional pain management care available anywhere. Our Center includes a comfortable, state-of-the-art medical facility, pleasant and well-trained personnel, physicians trained in the most advanced orthopaedic treatments, interventional pain management procedures, regenerative medicine, using stem cell and platelet therapies and a dedication to old-fashioned patient care.

View original content to download multimedia:http://www.prnewswire.com/news-releases/orthopaedic-surgeon-dr-jeffrey-carlson-first-in-central-and-eastern-virginia-to-implant-the-m6-c-artificial-cervical-disc-300976419.html

SOURCE Orthopaedic & Spine Center

Read the original:
Orthopaedic Surgeon, Dr. Jeffrey Carlson, first in Central and Eastern Virginia to implant the M6-C Artificial Cervical Disc - BioSpace